GlassScriptPhysician profile
Jenna E Mcmillan
NPI 1760283436
$2,087.93
in general payments reported to CMS, 2019-2025
19 companies · $1,967 in 2025
The $1,967 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $121 · 2025: $1,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,970.56 |
| Education | $117.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $268.28 | 2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $219.53 | 2025 | Dupixent |
| Lilly USA, LLC | $168.99 | 2024-2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $168.70 | 2025 | Glassia |
| Verona Pharma, INC. | $160.44 | 2025 | Ohtuvayre |
| Janssen Biotech, INC. | $149.86 | 2025 | Carvykti, Rybrevant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.96 | 2025 | Jascayd, Ofev |
| Harmony Biosciences LLC | $141.65 | 2025 | |
| Grifols USA, LLC | $111.22 | 2025 | Prolastin-C Liquid |
| Genzyme Corporation | $93.29 | 2025 | |
| Insmed, INC. | $83.09 | 2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $77.42 | 2025 | Uptravi |
| Astrazeneca Pharmaceuticals LP | $75.39 | 2025 | Fasenra, Airsupra |
| Mallinckrodt Hospital Products INC. | $71.92 | 2025 | Acthar |
| Baxter Healthcare | $46.07 | 2025 | Hillrom - Vest System Model 105 Home Care |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $45.63 | 2025 | Vest Therapy Und |
| Abbvie INC. | $22.12 | 2025 | |
| Fisher & Paykel Healthcare INC | $19.68 | 2025 | Fisher & Paykel Healthcare |
| Hikma Pharmaceuticals USA | $16.69 | 2025 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Mcmillan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.